Vivanza Biosciences Limited has submitted its unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, to the Bombay Stock Exchange. The filing, dated August 8, 2026, discloses that the company’s Board of Directors approved the financial statements on August 7, 2026, after they were reviewed by the Audit Committee. This submission ensures regulatory compliance and provides investors with updated performance metrics for the initial quarter of FY27.

The intimation was issued under Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Jayendra Amichand Mehta, Managing Director of Vivanza Biosciences, signed the communication to the Corporate Relationship Department at BSE Limited. The company also published extracts of the financial results along with the limited review report in The Indian Express (English) and Financial Express (Gujarati), adhering to disclosure norms for regional accessibility.

Financial Review Details

The filing confirms that the full format of the financial results is available on the stock exchange websites and the company’s official portal. While the specific numerical values for revenue, profit, or other key performance indicators are not detailed in this intimation letter, the document serves as a formal notification of the availability of these figures for stakeholder review.

Shareholder Information

Alongside the financial results, Vivanza Biosciences highlighted a special window for the transfer and dematerialization of physical securities. In accordance with SEBI Circular No. HO/38/13/11(2) 2026-MIRSD-POD/1/3750/2026, the special window has been extended from February 5, 2026, to February 4, 2027. This facility allows shareholders to re-lodge transfer requests for physical shares that were previously rejected or returned due to deficiencies in documents or processes prior to April 1, 2019.

Eligible shareholders must ensure their ledger has a demat account and provide a Client Master List (CML) along with transfer documents and share certificates. All transfers processed during this period will be issued only in dematerialized form. Shareholders are advised to contact the Registrar to the Issue and Share Transfer Agent (RTA), Purva Shareregistry (I) Ltd, for further assistance.

Vivanza Biosciences Limited reported a return to profitability in Q1FY26, posting a standalone net profit of ₹14.51 lakh compared to a net loss of ₹26.61 lakh in the previous quarter. The company’s revenue from operations rose 16.9% year-on-year to ₹914.09 lakh, signaling improved operational momentum. This turnaround is significant for shareholders as it marks a shift from consecutive losses in the prior period, stabilizing earnings for the current fiscal start.

The Board of Directors approved the unaudited standalone and consolidated financial results on August 7, 2026, at its meeting held at the registered office in Ahmedabad. The results were reviewed by Shivam Soni & Co., the statutory auditors, under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The limited review report confirmed that the financial statements present true and fair views without material misstatement.

Financial Performance Highlights

The company’s top-line growth was supported by higher revenue from operations, which stood at ₹914.09 lakh in Q1FY26, up from ₹782.06 lakh in the same quarter last year. On a consolidated basis, revenue reached ₹928.97 lakh, an increase of 4.1% year-on-year from ₹893.92 lakh. Other income contributed ₹37.28 lakh to the total income, a substantial rise from ₹1.74 lakh in Q1FY25.

On the cost side, purchase of stock-in-trade amounted to ₹932.73 lakh, while employee benefits expense was ₹9.56 lakh. Finance costs remained relatively stable at ₹10.62 lakh. The profit before tax stood at ₹18.08 lakh, against a loss of ₹12.32 lakh in the previous quarter.

What the Numbers Show

A key observation from the filing is the significant contribution of other income to the bottom line. While revenue grew steadily, other income jumped to ₹37.28 lakh from just ₹0.77 lakh in the previous quarter and ₹1.74 lakh year-on-year. This non-operational income component played a crucial role in driving the net profit turnaround, as operational margins remain thin with total expenses closely tracking total income. Investors should monitor whether this other income is recurring or one-off in nature for future quarters.

The company operates in three segments: Pharmaceuticals, Agro, and Film-related activities. The consolidated results include the subsidiary Vivanza Lifesciences Private Limited. Earnings per share (basic and diluted) were ₹0.04 for the quarter, compared to a loss of ₹0.07 per share in Q4FY25.